Immatics NV (IMTX) Stock: What Does the Chart Say Friday?

Immatics NV (IMTX) stock is down 6.00% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Immatics NV has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on IMTX!

See Full IMTX Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With IMTX Stock Today?

Immatics NV (IMTX) stock is trading at $11.29 as of 12:42 PM on Friday, Mar 22, a decline of -$0.05, or -0.44% from the previous closing price of $11.34. The stock has traded between $11.14 and $11.50 so far today. Volume today is light. So far 168,729 shares have traded compared to average volume of 454,607 shares.

More About Immatics NV

Immatics NV is engaged in the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's pipeline consists of two lead product classes, engineered Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics (TCER). Each therapeutic modality has distinct attributes to produce the desired therapeutic effect for patients at different disease stages and with different types of tumors focusing on particularly hard-to-treat solid cancers. Click Here to get the full Stock Report for Immatics NV stock.